Kert Viele, Discover and Read the Best of Twitter Threads by @KertViele

Kert Viele

KertViele

(1/n) Saw this letter in @NEJM…also covered by journalists. Concurrent vs non-concurrent controls is a complex issue in platform trials. This is a tweetorial on these issues, and a comment

(1/n) Tweetorial…When people talk about a trial “stopping early”, that implies there is an “on time”. Standard trials really “look late”, and interim analyses bridge the gap. Examples in terms

(1/n) The Pfizer SARS-Cov-2 vaccine trial has 4 interim analyses. Each interim has a set number of events and certain splits result in declaring efficacy or futility. If they were

(1/12) I receive emails warning about hackers targeting COVID data. Huge issues..it’s a crime and a danger to trial integrity. But also begs another discussion…if your loved one could be

(1/6) Interesting discussion on REMAPCAP and AI. I first thought ”ick, an unnecessary sidebar to the real innovations”, then “maybe it’s AI in an overly broad sense of AI”….and now

(1/20) Tweetorial on this statement…”…red flag…The investigators….already taken an interim look…did not stop the study early….dampens optimism for an overall positive outcome”Is this a red flag? Maybe…maybe not…depends on how